Intellia Therapeutics Announces Third Quarter 2023 Financial

FDA cleared NTLA-2001 IND application for first in vivo CRISPR candidate to enter late-stage clinical development; on track to initiate the MAGNIT...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , London , City Of , Spain , Madrid , Ian Karp , John Leonard , Alina Li , Matt Crenson , Corporate Communications , Intellia Therapeutics Inc , Exchange Commission , Regeneron Pharmaceuticals Inc , Vivo Program Updates , Nasdaq , Company At The Market , Twitter , Drug Administration , European Medicines Agency , Clinical Trial Application , Intellia President , Chief Executive Officer John Leonard , Recent Operational , New Drug , Priority Medicine , Associated Lung Disease , Associated Liver Disease , Jefferies London Healthcare Conference , Discuss Third Quarter , Intellia Therapeutics , Private Securities Litigation Reform Act , Regeneron Pharmaceuticals , Months Ended September , Vice President , Investor Relations ,